Cognex Corp Q4 Profit Climbs

Cognex reported Q4 GAAP net income of $32.66 million ($0.19/share) versus $28.34 million ($0.16) a year earlier, with adjusted earnings of $46.35 million ($0.27/share). Revenue rose 9.9% year-over-year to $252.33 million from $229.68 million, and the company issued Q1 guidance of $0.22–$0.26 EPS and $235M–$255M in revenue, signaling continued top-line growth and modestly improved profitability.

Analysis

Market structure: Cognex's 9.9% revenue growth and midpoint Q1 guidance roughly flat vs Q4 (252M vs midpoint ~245M) signal durable demand for machine-vision in logistics/semiconductor but near-term seasonality and cautious capex. Direct winners: CGNX, software integrators, and logistics automation providers; losers: manual inspection services and low‑end Chinese vision vendors if ASPs hold. Cross-asset: stronger CGNX prints should compress credit spreads for niche industrial tech and depress options IV; a stronger USD remains a tailwind for US importers but a translation headwind for CGNX international sales.

Risk assessment: Tail risks include a sudden industrial capex pullback (>10% YoY decline in orders), export controls on advanced imaging, or loss of a >10% customer; these would materialize in 30–90 days and hit revenue/backlog hard. Hidden dependencies: customer concentration (large OEMs), sensor supply constraints, and exposure to auto/semiconductor cycles can amplify moves. Key catalysts: next-quarter order backlog disclosure, ISM/manufacturing PMIs, and major customers' capex guidance over the next 1–3 months.

Trade implications: Tactical long CGNX positions (size 2–4% portfolio) capture secular AI/warehouse automation adoption; prefer defined‑risk options (buy 6‑month call spreads 10–15% OTM sized at 0.5–1% portfolio) to lever upside without open tail risk. Relative value: pair long CGNX / short TDY (0.6x) for 6–12 months to isolate machine‑vision outperformance vs diversified imaging/electronics exposure. Rotate into industrial automation (ROBO/automation names) and trim legacy test/equipment cyclicals.

Contrarian angles: Consensus underweights structural demand from e‑commerce/AI inspection that could drive 15–25% TAM expansion over 2–3 years; conversely guidance may be conservatively priced and a beat could drive a 20–30% re‑rating. Risks underappreciated by the market include low‑cost competition compressing ASPs over 1–3 years and rapid capex reversals that would make current valuation fragile.

Key Decisions for Investors

• Establish a 2–4% long position in CGNX (Cognex) over the next 2–4 weeks (scale 50% now, 50% on up to 5% pullback). Target +20–30% upside in 6–12 months; place stop-loss at -12% from average entry.
• Buy a defined‑risk options position: purchase a 6‑month CGNX call spread with strikes ~10–15% OTM sized at 0.5–1% of portfolio capital to capture upside if Q1 revenue beats the midpoint and order backlog is healthy.
• Implement a pair trade: long CGNX (1x) / short Teledyne Technologies (TDY) (0.6x) for 6–12 months to express machine‑vision outperformance; trim/close if CGNX outperforms TDY by >8% or if CGNX misses revenue guidance by >3%.
• Reduce exposure to broad automation/robotics cyclicals (example: trim FANUY by ~15%) over the next 3 months given auto capex cyclicality; redeploy proceeds into CGNX/ROBO names if ISM manufacturing PMIs stay >=50 for two consecutive months.
• Exit or cut positions within 5 trading days if CGNX reports next-quarter revenue below the guidance midpoint by >3% or discloses a material (>10%) customer loss or backlog decline (book‑to‑bill <0.9).